Cargando…

Anti‐TNF‐induced lupus in patients with inflammatory bowel disease

BACKGROUND AND AIMS: Anti‐Tumor Necrosis Factor (TNF)‐induced lupus (ATIL) is a distinct clinical entity, increasingly recognized in patients with inflammatory bowel disease treated with anti‐TNF therapy. Our aims were to evaluate the incidence and clinical and serological markers of ATIL in this po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Picardo, Sherman, So, Kenji, Venugopal, Kannan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273700/ https://www.ncbi.nlm.nih.gov/pubmed/32514462 http://dx.doi.org/10.1002/jgh3.12291

Ejemplares similares

Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study
por: Jeffrey, Angus W., et al.
Publicado: (2023)

Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience
por: Jeffrey, Angus W., et al.
Publicado: (2023)

Anti-TNF Withdrawal in Inflammatory Bowel Disease
por: Torres, Joana, et al.
Publicado: (2016)

Complementary and alternative medications in the management of inflammatory bowel disease
por: Picardo, Sherman, et al.
Publicado: (2020)

Insights into the role of cannabis in the management of inflammatory bowel disease
por: Picardo, Sherman, et al.
Publicado: (2019)

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
por: Cachen, Laurie, et al.
Publicado: (2022)

Anti-TNF-alpha-induced lupus
por: De Bandt, Michel
Publicado: (2019)

Mucosal gene expression changes induced by anti‐TNF treatment in inflammatory bowel disease patients
por: Milanesi, Elena, et al.
Publicado: (2019)

Pott’s Puffy Tumor in an Inflammatory Bowel Disease Patient on Anti-TNF Therapy
por: Miri, Ahmad, et al.
Publicado: (2021)

Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
por: Orfanoudaki, Eleni, et al.
Publicado: (2023)

A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy
por: Chebli, Júlio Maria Fonseca, et al.
Publicado: (2014)

Investigation of the effects of anti-TNF agents on hemoglobin levels in patients with inflammatory bowel disease
por: Okuyucu, Muhammed, et al.
Publicado: (2022)

Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients
por: Cha, Jae Myung, et al.
Publicado: (2017)

Specific T-Cell Subsets Can Predict the Efficacy of Anti-TNF Treatment in Inflammatory Bowel Diseases
por: Dulic, Sonja, et al.
Publicado: (2020)

A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease
por: Aardoom, Martine A., et al.
Publicado: (2019)

Leishmania infantum asymptomatic infection in inflammatory bowel disease patients under anti-TNF therapy
por: Guillén, M. Carmen, et al.
Publicado: (2020)

Serum Levels of Chemerin in Patients with Inflammatory Bowel Disease as an Indicator of Anti-TNF Treatment Efficacy
por: Sochal, Marcin, et al.
Publicado: (2021)

Anti-TNF-α and hydralazine drug-induced lupus
por: Quaresma, Maria Victória, et al.
Publicado: (2015)

Anti-TNF therapy for inflammatory bowel disease in patients with neurodegenerative Niemann-Pick disease Type C
por: Williams, Isabelle, et al.
Publicado: (2022)

Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2020)

Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2021)

TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease
por: Altwegg, Romain, et al.
Publicado: (2014)

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
por: Eun, Chang Soo
Publicado: (2017)

Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy
por: Dahmus, Jessica, et al.
Publicado: (2020)

Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers
por: Cui, Guanglin, et al.
Publicado: (2021)

Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report
por: Mohagheghi Darehranj, Samaneh, et al.
Publicado: (2020)

Cyclin-dependent Kinase 9 as a Potential Target for Anti-TNF-resistant Inflammatory Bowel Disease
por: Omer, Omer S., et al.
Publicado: (2022)

IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease
por: Strobel, Thomas, et al.
Publicado: (2020)

Rate and Predictors of Mucosal Healing in Patients with Inflammatory Bowel Disease Treated with Anti-TNF-Alpha Antibodies
por: Beigel, Florian, et al.
Publicado: (2014)

Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease
por: Paschou, Stavroula A., et al.
Publicado: (2018)

An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease
por: Patel, Rajan N., et al.
Publicado: (2020)

Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: a hospital-based cohort study from Korea
por: Choi, Su Jin, et al.
Publicado: (2021)

Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study
por: Marin-Jimenez, Ignacio, et al.
Publicado: (2020)

Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease
por: Schultheiss, Johannes P. D., et al.
Publicado: (2021)

Anti-TNF-α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease
por: Zhang, Cui, et al.
Publicado: (2018)

TNF-Alpha Gene Polymorphisms in Iranian Azari Turkish Patients with Inflammatory Bowel Diseases
por: Bonyadi, Mortaza, et al.
Publicado: (2014)

Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
por: Gisbert, Javier P., et al.
Publicado: (2021)

FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNFα Agents
por: Guidi, Luisa, et al.
Publicado: (2013)

Systematic review: genetic biomarkers associated with anti‐TNF treatment response in inflammatory bowel diseases
por: Bek, S., et al.
Publicado: (2016)

Potential Impact of Diet on Treatment Effect from Anti-TNF Drugs in Inflammatory Bowel Disease
por: Andersen, Vibeke, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p5808pusp2oedfg33gottet5ko